S1014 Immune Checkpoint Inhibitors for Colorectal Cancer in Patients With Inflammatory Bowel Disease

医学 结直肠癌 内科学 微卫星不稳定性 炎症性肠病 癌症 彭布罗利珠单抗 肿瘤科 林奇综合征 相伴的 胃肠病学 疾病 免疫疗法 DNA错配修复 化学 等位基因 基因 微卫星 生物化学
作者
David M. Faleck,Konika Sharma,Rona D. Yaeger,David Paul Kelsen
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:117 (10S): e734-e735
标识
DOI:10.14309/01.ajg.0000860696.14687.ed
摘要

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the management of many types of malignancies, including microsatellite instability high (MSI-H) colorectal cancers (CRC), but pose a unique challenge to patients with underlying inflammatory disorders such as inflammatory bowel disease (IBD). The safety and efficacy of ICI therapy for CRC in patients with underlying IBD has not been described. Methods: We queried the electronic health database for patients with IBD and CRC who were treated with ICI at tertiary care cancer center in New York City. We collected demographic data, IBD and cancer history, and outcomes of both IBD and CRC after treatment with ICIs. Results: Four patients with underlying IBD were treated with ICIs for MSI-H colorectal cancer (Table). All patients had long-standing IBD for greater than 20 years. Two of the patients were diagnosed with concomitant Lynch syndrome at the time of MSI-H cancer diagnosis. No patients were on active IBD therapies at the time of ICI initiation. All four patients were treated with anti-PD-1 therapy (Pembrolizumab) for stage 3 (n=2) or stage 4 (n=2) CRC. All four patients had robust cancer responses to ICI, three with partial responses and one with a complete response over a median follow-up time of 34 months. One patient with locally advanced rectal cancer had a complete response and has avoided the need for surgical resection and permanent stoma.Three patients had a flare of IBD while on ICI requiring initiation of 5-ASA (n=2) or immunosuppressive therapy (n=1) (Table). One patient required hospitalization for IBD flare. ICI therapy was held due to IBD flare for two patients who had already achieved significant response to ICI with stable disease. Conclusion: In this small series of patients with IBD and MSI-H colorectal cancer, treatment with ICIs was effective at achieving cancer response in all patients while IBD flares were common but manageable with standard medical therapy. Larger studies are needed to explore the safety and efficacy of ICIs for CRC in patients with IBD. Table 1. - Baseline Characteristics and Outcomes of CRC and IBD after ICI Therapy Patient Age of ICI Initiation & IBD type IBD Duration (years) & Prior IBD Medications Lynch Syndrome Cancer Stage ICI Type & Doses of ICI Treatment for IBD Flare Best overall Cancer Response to ICI Surgery for CRC 1 51, Crohn's 38; SSZ, CS, IFX No IV PD- 1, 33 Prednisone, Adalimumab, Ustekinumab Partial Response Subtotal colectomy (before ICI) 2 50, Crohn's 23; 6-MP No IV PD- 1, 10 N/A Partial Response Total proctocolectomy with end ileostomy (before ICI) 3 35, UC 22; 5-ASA Yes III PD- 1, 33 5-ASA Complete Response None 4 34, UC 22; 5-ASA, CS,AZA Yes III PD- 1, 4 5-ASA Partial Response Total proctocolectomy with ileoanal anastomosis (after ICI) ADA: adalimumab, AZA: azathioprine; CRC- Colorectal Cancer; CS: corticosteroids; CTCAE: Common Terminology Criteria for Adverse Events, IBD: inflammatory bowel disease, ICI: immune checkpoint inhibitor; IFX: infliximab; PD-1: Programmed Death 1; SSZ: sulfasalazine; 5-ASA: 5-aminosalicylate; 6- MP : 6-mercaptopurine; UC: ulcerative colitis
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小金鱼8569完成签到,获得积分10
3秒前
随心所欲完成签到 ,获得积分0
3秒前
苗条的白梅完成签到,获得积分10
3秒前
xybjt完成签到 ,获得积分10
5秒前
大呲花完成签到,获得积分10
9秒前
成就苞络完成签到,获得积分10
11秒前
w0r1d完成签到 ,获得积分10
11秒前
xiaojinyu195完成签到,获得积分10
13秒前
xiaojinyu131完成签到,获得积分10
23秒前
Connie425完成签到 ,获得积分10
23秒前
alixy完成签到,获得积分10
23秒前
萌萌2完成签到,获得积分10
32秒前
爱沉淀的太阳花完成签到,获得积分10
33秒前
35秒前
xiaoxiao完成签到 ,获得积分10
37秒前
LingMg完成签到 ,获得积分10
37秒前
丰富的澜完成签到 ,获得积分10
39秒前
文文完成签到 ,获得积分10
41秒前
Brave发布了新的文献求助10
41秒前
妙海完成签到,获得积分10
41秒前
萌萌1完成签到,获得积分10
42秒前
灵巧的谷南完成签到 ,获得积分10
43秒前
小鱼崽完成签到 ,获得积分10
44秒前
666666神花露水完成签到 ,获得积分10
45秒前
CipherSage的应助被豆豆采纳,获得10
45秒前
幸福的映容完成签到 ,获得积分10
47秒前
馨妈完成签到 ,获得积分10
47秒前
JinwenShi完成签到,获得积分10
49秒前
欢喜语柳完成签到 ,获得积分10
50秒前
魔幻的晓灵完成签到,获得积分10
56秒前
hxs606完成签到 ,获得积分10
57秒前
温暖的寻雪完成签到 ,获得积分10
58秒前
科研通AI6.2的应助被孙丽菲采纳,获得10
1分钟前
凝望星空完成签到,获得积分10
1分钟前
科研助理完成签到 ,获得积分10
1分钟前
冷酷的祥完成签到,获得积分10
1分钟前
彦成完成签到,获得积分10
1分钟前
无语的易烟完成签到 ,获得积分10
1分钟前
1分钟前
微笑的巧蕊完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012